March 19 (Reuters) - GlaxoSmithKline Plc's drug totreat chronic breathing problems is safe and effective enough tobe approved in adults with asthma but not adolescents, anadvisory panel to the U.S. Food and Drug Administrationconcluded on Thursday.
The panel voted 16 to 4 that the product, Breo Ellipta,should be approved for once daily treatment of asthma in adults18 years and older. It voted 19 to 1 that the data did notsupport approval for use in children aged 12 to 17.
The FDA is not obliged to follow the advice of its advisorypanels but typically does so. Glaxo licensed the product fromTheravance Inc in 2002. (Reporting by Toni Clarke in Washington; Editing by SandraMaler)